Turnover and distribution of intravenously administered mannose-terminated human acid beta-glucosidase in murine and human tissues.
Gaucher disease type 1, the most prevalent lysosomal storage disease, is caused by the defective activity of the lysosomal enzyme, acid beta-glucosidase, or glucocerebrosidase. Infusion of purified acid beta-glucosidase containing alpha-mannosyl-terminated oligosaccharides (alglucerase) is efficacious in reversing hematologic, hepatic, splenic, and bony disease manifestations. The murine tissue distribution and turnover of bolus injections of alglucerase was evaluated by enzymatic activity, quantitative cross-reacting immunologic material analyses, and immunofluorescence studies. Enzyme activity measurements detected distribution to liver, spleen, thymus, kidney, and bone marrow mononuclear cells, but not to lungs and brain. In kidney and thymus, the enzyme was transiently present. In liver and spleen, enzyme activity peaked at about 20 min postinjection followed by a biphasic decrease with t1/2 approximately 40-60 min and approximately 12-14 h. In bone marrow maximal enzyme activity was at 40-60 min with a disappearance t1/2 approximately 60 min. Quantitative cross-reacting immunologic material studies of liver and spleen showed delivery of enzyme with decreased catalytic rate constants whose degradation included denaturation and proteolytic components. By immunofluorescence the human enzyme was distributed primarily to reticuloendothelial cells of the liver and spleen. In autopsy material from a Gaucher disease type 2 patient treated with enzyme, immunohistochemical and activity studies showed distributions similar to those in mice. These studies indicate a complex delivery and intracellular degradation of acid beta-glucosidase with lower intrinsic activity than the administered therapeutic agent.
Xu
Y H
YH
Division of Human Genetics, Children's Hospital Research Foundation, Cincinnati, Ohio, USA.
Ponce
E
E
Sun
Y
Y
Leonova
T
T
Bove
K
K
Witte
D
D
Grabowski
G A
GA
D000818:Animals; D004195:Disease Models, Animal; D005776:Gaucher Disease / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D005962:Glucosylceramidase / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D008099:Liver / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D013154:Spleen / Q000378:metabolism
C070292:alglucerase; D005962:Glucosylceramidase